Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964769 | PMC |
| http://dx.doi.org/10.1038/s41598-022-09460-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to 'Decreased Blood Pressure With Acute Administration of Quercetin in L-NAME-Induced Hypertensive Rats'.
Basic Clin Pharmacol Toxicol
February 2025
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema.
Int J Retina Vitreous
January 2025
Army Hospital Research & Referral, Delhi Cantt, New Delhi, Delhi, 110010, India.
Background: Management of Diabetic Macular edema (DME) requires repeated injections. Therefore newer Anti-VEGFs like Brolucizumab with longer durability have been introduced. We compared two different dosages of Brolucizumab, 6.
View Article and Find Full Text PDFCorrection: Bubbling insights: unveiling the true sophorolipid biosynthetic pathway by Starmerella bombicola.
Biotechnol Biofuels Bioprod
January 2025
Centre for Industrial Biotechnology and Biocatalysis (InBio.be), Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000, Ghent, Belgium.
Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI).
Cardiovasc Diabetol
January 2025
Division of Cardiology, Sant'Andrea Hospital, Rome, Italy.
Correction to: Peripheral signaling pathways contributing to non-histaminergic itch in humans.
J Transl Med
January 2025
Research Group Neuroscience, Interdisciplinary Centre for Clinical Research, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!